Erenna Immunoassay System: Cutting-edge technology for biomarker research
The Singulex Erenna Immunoassay System represents a major advance in biomarker research. With its single molecule counting (SMC) technology, Erenna offers unmatched sensitivity and accuracy, enabling researchers to detect and quantify biomarkers at extremely low levels. This ability to measure minute changes in biomarker levels opens new possibilities for understanding complex diseases, evaluating drug efficacy, and ensuring patient safety.
The Erenna system is designed to follow a workflow similar to that of traditional ELISA technology, but with significantly improved performance. By combining a unique elution step with robust digital counting, SMC technology achieves improved signal-to-noise ratios compared to traditional immunoassay technologies. This enables accurate quantification at both low and high expression levels on a complete system.
The Erenna instrument captures the sum of all counted digital events. At high concentrations, a proprietary algorithm calculates the total sum of all recorded photons. As a result, SMC technology improves assay sensitivity and extends the dynamic measurement range well beyond what could be achieved with traditional technologies.
The Erenna system is ideal for research laboratories that require high accuracy and sensitivity for their biomarker studies. It is particularly useful for research in oncology, neurology, cardiology, and immunology, where early and accurate detection of biomarkers can make a significant difference in patient outcomes.
The Erenna Immunoassay system from Singulex is a complete solution for biomarker research. With its SMC technology, it offers unmatched sensitivity and accuracy, enabling researchers to make groundbreaking discoveries and improve outcomes for patients.